title: Cystoid macular edema associated with ocular hypotensive lipids.
abstract: OBJECTIVE
  To report angiographically documented cystoid macula edema associated with the use of each of the three newly available ocular hypotensive lipids: unoprostone, travaprost, and bimatoprost.
  
  
  METHODS
  Observational case series.
  
  
  METHODS
  Retrospective review of three patients in a clinical practice who had uncontrolled glaucoma on maximal tolerable therapy except for an ocular hypotensive lipids. All three patients also had previous cataract and filtration surgery, and all had an absent or open posterior lens capsule. The patients were informed of the potential risks of cystoid macula edema associated with the use of an ocular hypotensive lipids versus the risks of repeat filtration surgery.
  
  
  RESULTS
  An ocular hypotensive lipids was started in the affected eye in each patient, and the patient was instructed to check visual acuity everyday and report back any change in vision occurred.
  
  
  CONCLUSIONS
  Decreased vision of at least two lines caused by angiographically confirmed cystoid macula edema was noted in each of three patients started, respectively, on unoprostone, travaprost, and bimatoprost. The visual acuity returned to baseline, and the cystoid macula edema was angiographically resolved after discontinuation of the ocular hypotensive lipids and the initiation of a topical steroid and non-steroidal anti-inflammatory eyedrops. Until a causal relationship between cystoid macula edema and ocular hypotensive lipids is proved or disproved, caution in their use in high-risk eyes would be prudent.
authors.affiliation: University of Connecticut School of Medicine, Farmington, Connecticut, USA. nodhilwand@aol.com
authors.forename: Martin
authors.initials: M
authors.lastname: Wand
authors.forename: Alexander R
authors.initials: AR
authors.lastname: Gaudio
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000577:Amides; D000959:Antihypertensive Agents / Q000009:adverse effects*; D000069580:Bimatoprost; D003008:Cloprostenol / Q000009:adverse effects* / Q000031:analogs & derivatives; D015237:Dinoprost / Q000009:adverse effects* / Q000031:analogs & derivatives*; D005260:Female; D005451:Fluorescein Angiography; D005901:Glaucoma / Q000188:drug therapy; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D019654:Lens Implantation, Intraocular; D008055:Lipids / Q000009:adverse effects*; D008269:Macular Edema / Q000139:chemically induced*; D008297:Male; D018918:Phacoemulsification; D012189:Retrospective Studies; D014130:Trabeculectomy; D000069557:Travoprost; D014792:Visual Acuity
chemical_list: D000577:Amides; D000959:Antihypertensive Agents; D008055:Lipids; D003008:Cloprostenol; C072630:isopropyl unoprostone; D015237:Dinoprost; D000069580:Bimatoprost; D000069557:Travoprost